- 1.
- 2.
National Institute for Health and Care Excellence. Bisphosphonates for Treating Osteoporosis. 2017. URL:
www.nice.org.uk/guidance/ta464 (accessed June 2022).
- 3.
Freemantle
N, Cooper
C, Diez-Perez
A, Gitlin
M, Radcliffe
H, Shepherd
S, Roux
C. Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int
2013;24:209–17.
[
PMC free article: PMC3662000] [
PubMed: 22832638]
- 4.
Saito
T, Sterbenz
JM, Malay
S, Zhong
L, MacEachern
MP, Chung
KC. Effectiveness of antiosteoporotic drugs to prevent secondary fragility fractures: systematic review and metaanalysis. Osteoporos Int
2017;28:3289–300.
[
PubMed: 28770272]
- 5.
Compston
J, Cooper
A, Cooper
C, Gittoes
N, Gregson
C, Harvey
N, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos
2017;12:43–9.
[
PMC free article: PMC5397452] [
PubMed: 28425085]
- 6.
- 7.
Hawley
S, Javaid
MK, Rubin
KH, Judge
A, Arden
NK, Vestergaard
P, et al. Incidence and predictors of multiple fractures despite high adherence to oral bisphosphonates: a binational population-based Cohort study. J Bone Miner Res
2016;31:234–44.
[
PubMed: 26174968]
- 8.
Dugard
MN, Jones
TJ, Davie
MW. Uptake of treatment for osteoporosis and compliance after bone density measurement in the community. J Epidemiol Community Health
2010;64:518–22.
[
PubMed: 19679704]
- 9.
- 10.
- 11.
Siris
ES, Gehlbach
S, Adachi
JD, Boonen
S, Chapurlat
RD, Compston
JE, et al. Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW). Osteoporos Int
2011;22:27–35.
[
PMC free article: PMC3017306] [
PubMed: 20358360]
- 12.
Roh
YH, Koh
YD, Noh
JH, Gong
HS, Baek
GH. Effect of health literacy on adherence to osteoporosis treatment among patients with distal radius fracture. Arch Osteoporos
2012;12:42–8. [
PubMed: 28421547]
- 13.
Modi
A, Fan
CS, Tang
J, Weaver
JP, Sajjan
S. Association of gastrointestinal events with osteoporosis treatment initiation and treatment compliance in Germany: an observational study. Bone Rep
2016;5:208–13.
[
PMC free article: PMC5440957] [
PubMed: 28580388]
- 14.
Raybould
G, Babatunde
O, Evans
AL, Jordan
JL, Paskins
Z. Expressed information needs of patients with osteoporosis and/or fragility fractures: a systematic review. Arch Osteoporos
2018;13:14–9.
[
PMC free article: PMC5938310] [
PubMed: 29736627]
- 15.
Cramer
JA, Roy
A, Burrell
A, Fairchild
CJ, Fuldeore
MJ, Ollendorf
DA, Wong
PK. Medication compliance and persistence: terminology and definitions. Value Health
2008;11:44–7.
[
PubMed: 18237359]
- 16.
Karlsson
L, Lundkvist
J, Psachoulia
E, Intorcia
M, Strom
O. Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int
2015;26:2401–11.
[
PMC free article: PMC4575381] [
PubMed: 26282229]
- 17.
Cramer
JA, Gold
DT, Silverman
SL, Lewiecki
EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int
2007;18:1023–31.
[
PubMed: 17308956]
- 18.
Recknor
C, Czerwinski
E, Bone
HG, Bonnick
SL, Binkley
N, Palacios
S, et al. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol
2013;121:1291–9.
[
PubMed: 23812464]
- 19.
Akarırmak
U, Koçyiğit
H, Eskiyurt
N, Esmaeilzadeh
S, Kuru
O, Yalçinkaya
EY, et al.; INSTRUCT Study Group. Influence of patient training on persistence, compliance, and tolerability of different dosing frequency regimens of bisphosphonate therapy: an observational study in Turkish patients with postmenopausal osteoporosis. Acta Orthop Traumatol Turc
2016;50:415–23.
[
PMC free article: PMC6197458] [
PubMed: 27524671]
- 20.
Kishimoto
H, Maehara
M. Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA. Arch Osteoporos
2015;10:231–9.
[
PMC free article: PMC4545179] [
PubMed: 26297076]
- 21.
Durden
E, Pinto
L, Lopez-Gonzalez
L, Juneau
P, Barron
R. Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. Arch Osteoporos
2017;12:22–9.
[
PMC free article: PMC5329075] [
PubMed: 28243883]
- 22.
Svedbom
A, Hernlund
E, Ivergård
M, Compston
J, Cooper
C, Stenmark
J, et al.; EU Review Panel of IOF. The EU review panel of the IOF Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos
2013;8:137–42.
[
PMC free article: PMC3880492] [
PubMed: 24113838]
- 23.
Williamson
S, Landeiro
F, McConnell
T, Fulford-Smith
L, Javaid
MK, Judge
A, Leal
J. Costs of fragility hip fractures globally: a systematic review and meta-regression analysis. Osteoporos Int
2017;28:2791–800.
[
PubMed: 28748387]
- 24.
Borgström
F, Zethraeus
N, Johnell
O, Lidgren
L, Ponzer
S, Svensson
O, et al. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int
2006;17:637–50.
[
PubMed: 16283064]
- 25.
Tarride
JE, Burke
N, Leslie
WD, Morin
SN, Adachi
JD, Papaioannou
A, et al. Loss of health related quality of life following low-trauma fractures in the elderly. BMC Geriatr
2016;16:84–91.
[
PMC free article: PMC4837505] [
PubMed: 27093957]
- 26.
- 27.
Ross
S, Samuels
E, Gairy
K, Iqbal
S, Badamgarav
E, Siris
E. A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health
2011;14:571–81.
[
PubMed: 21669382]
- 28.
Shalev
V, Sharman Moser
S, Goldshtein
I, Yu
J, Weil
C, Ish-Shalom
S, et al. Adherence With bisphosphonates and long-term risk of hip fractures: a nested case-control study using real-world data. Ann Pharmacother
2017;51:757–67.
[
PubMed: 28535690]
- 29.
- 30.
- 31.
- 32.
- 33.
- 34.
Shu
AD, Stedman
MR, Polinski
JM, Jan
SA, Patel
M, Truppo
C, et al. Adherence to osteoporosis medications after patient and physician brief education: post hoc analysis of a randomized controlled trial. Am J Manag Care
2009;15:417–24.
[
PMC free article: PMC2885859] [
PubMed: 19589009]
- 35.
- 36.
Seuffert
P, Sagebien
CA, McDonnell
M, O’Hara
DA. Evaluation of osteoporosis risk and initiation of a nurse practitioner intervention program in an orthopedic practice. Arch Osteoporos
2016;11:10–8.
[
PubMed: 26847628]
- 37.
Tuncel
T, Hasselberg
J, Peters
KM. Compliance of osteoporosis patients with additional specific osteoporosis-training course. Orthopade
2017;46:256–62.
[
PubMed: 27807608]
- 38.
Nieuwlaat
R, Wilczynski
N, Navarro
T, Hobson
N, Jeffery
R, Keepanasseril
A, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev
2014;2014:. CD000011 [
PMC free article: PMC7263418] [
PubMed: 25412402]
- 39.
Diez-Perez
A, Naylor
KE, Abrahamsen
B, Agnusdei
D, Brandi
ML, Cooper
C, et al.; Adherence Working Group of the International Osteoporosis Foundation and the European Calcified Tissue Society. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int
2017;28:767–74.
[
PMC free article: PMC5302161] [
PubMed: 28093634]
- 40.
Lee
S, Glendenning
P, Inderjeeth
CA. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int
2011;22:741–53.
[
PubMed: 20589368]
- 41.
Tremblay
E, Perreault
S, Dorais
M. Persistence with denosumab and zoledronic acid among older women: a population-based cohort study. Arch Osteoporos
2016;11:30–8. HTA Commissioned Call 18/27.
[
PubMed: 27679503]
- 42.
- 43.
Marshall
L, Wong
SM, Sahota
O. Innovative intravenous osteoporosis at home service. Age Ageing
2014;43:i10–1.
- 44.
- 45.
Davis
S, Martyn-St James
M, Sanderson
J, Stevens
J, Goka
E, Rawdin
A, et al. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technol Assess
2016;20:1–406. [
PMC free article: PMC5107884] [
PubMed: 27801641]
- 46.
Jha
S, Wang
Z, Laucis
N, Bhattacharyya
T. Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996–2012: an ecological analysis. J Bone Miner Res
2015;30:2179–87.
[
PubMed: 26018247]
- 47.
Saini
SD, Schoenfeld
P, Kaulback
K, Dubinsky
MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care
2009;15:22–33. [
PubMed: 19514806]
- 48.
- 49.
de Bekker-Grob
EW, Essink-Bot
ML, Meerding
WJ, Pols
HA, Koes
BW, Steyerberg
EW. Patients’ preferences for osteoporosis drug treatment: a discrete choice experiment. Osteoporos Int
2008;19:1029–37.
[
PMC free article: PMC2440927] [
PubMed: 18193329]
- 50.
Alten
R, Krüger
K, Rellecke
J, Schiffner-Rohe
J, Behmer
O, Schiffhorst
G, Nolting
HD. Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach. Patient Prefer Adherence
2016;10:2217–28.
[
PMC free article: PMC5098563] [
PubMed: 27843301]
- 51.
Feldstein
AC, Schneider
J, Smith
DH, Vollmer
WM, Rix
M, Glauber
H, et al. Harnessing stakeholder perspectives to improve the care of osteoporosis after a fracture. Osteoporos Int
2008;19:1527–40.
[
PubMed: 18373049]
- 52.
Bliuc
D, Eisman
JA, Center
JR. A randomized study of two different information-based interventions on the management of osteoporosis in minimal and moderate trauma fractures. Osteoporos Int
2006;17:1309–17.
[
PubMed: 16804739]
- 53.
Sekhon
M, Cartwright
M, Francis
JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res
2017;17:88–95.
[
PMC free article: PMC5267473] [
PubMed: 28126032]
- 54.
Dejean
D, Giacomini
M, Simeonov
D, Smith
A. Finding qualitative research evidence for Health Technology Assessment. Qual Health Res
2016;26:1307–17.
[
PubMed: 27117960]
- 55.
Carroll
C, Booth
A, Cooper
K. A worked example of ‘best fit’ framework synthesis: a systematic review of views concerning the taking of some potential chemopreventive agents. BMC Med Res Methodol
2011;11:29.
[
PMC free article: PMC3068987] [
PubMed: 21410933]
- 56.
Horne
R, Chapman
SCE, Parham
R, Freemantle
N, Forbes
A, Cooper
V. Understanding patients’ adherence-related Beliefs about Medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLOS ONE
2013;8:e80633.
[
PMC free article: PMC3846635] [
PubMed: 24312488]
- 57.
Lewin
S, Booth
A, Glenton
C, Munthe-Kaas
H, Rashidian
A, Wainwright
M, et al. Applying GRADE-CERQual to qualitative evidence synthesis findings: introduction to the series. Implement Sci
2018;13:34–29.
[
PMC free article: PMC5791040] [
PubMed: 29384079]
- 58.
Besser
SJ, Anderson
JE, Weinman
J. How do osteoporosis patients perceive their illness and treatment? Implications for clinical practice. Arch Osteoporos
2012;7:115–24.
[
PubMed: 23225289]
- 59.
Sale
JEM, Beaton
D, Sujic
R, Bogoch
ER. ‘If it was osteoporosis, I would have really hurt myself.’ Ambiguity about osteoporosis and osteoporosis care despite a screening programme to educate fragility fracture patients. J Eval Clin Pract
2010;16:590–6.
[
PubMed: 20102434]
- 60.
Sale
JEM, Hawker
G, Cameron
C, Bogoch
E, Jain
R, Beaton
D, et al. Perceived messages about bone health after a fracture are not consistent across healthcare providers. Rheumatol Int
2015;35:97–103.
[
PubMed: 24962740]
- 61.
- 62.
Hansen
CA, Abrahamsen
B, Konradsen
H, Pedersen
BD. Women’s lived experiences of learning to live with osteoporosis: a longitudinal qualitative study. BMC Womens Health
2017;17:17–26.
[
PMC free article: PMC5345268] [
PubMed: 28279157]
- 63.
Otmar
R, Reventlow
SD, Nicholson
GC, Kotowicz
MA, Pasco
JA. General medical practitioners’ knowledge and beliefs about osteoporosis and its investigation and management. Arch Osteoporos
2012;7:107–14.
[
PubMed: 23225288]
- 64.
Jaglal
SB, Carroll
J, Hawker
G, McIsaac
WJ, Jaakkimainen
L, Cadarette
SM, et al. How are family physicians managing osteoporosis?: qualitative study of their experiences and educational needs. Can Fam Physician
2003;49:462–8.
[
PMC free article: PMC2214200] [
PubMed: 12729242]
- 65.
Ailabouni
NJ, Nishtala
PS, Mangin
D, Tordoff
JM. General practitioners’ insight into deprescribing for the multimorbid older individual: a qualitative study. Int J Clin Pract
2016;70:261–76.
[
PubMed: 26918508]
- 66.
Sippli
K, Rieger
MA, Huettig
F. GPs’ and dentists’ experiences and expectations of interprofessional collaboration: findings from a qualitative study in Germany. BMC Health Serv Res
2017;17:179.
[
PMC free article: PMC5341464] [
PubMed: 28270205]
- 67.
Merle
B, Haesebaert
J, Bedouet
A, Barraud
L, Flori
M, Schott
AM, Dupraz
C. Osteoporosis prevention: where are the barriers to improvement in French general practitioners? A qualitative study. PLOS ONE
2019;14:e0219681.
[
PMC free article: PMC6634405] [
PubMed: 31310619]
- 68.
Merle
B, Dupraz
C, Haesebaert
J, Barraud
L, Aussedat
M, Motteau
C, et al. Osteoporosis prevention: where are the barriers to improvement in a French general population? A qualitative study. Osteoporos Int
2019;30:177–85.
[
PubMed: 30306220]
- 69.
Drew
S, Judge
A, Cooper
C, Javaid
MK, Farmer
A, Gooberman-Hill
R. Secondary prevention of fractures after hip fracture: a qualitative study of effective service delivery. Osteoporos Int
2016;27:1719–27.
[
PMC free article: PMC4839047] [
PubMed: 26759249]
- 70.
Alami
S, Hervouet
L, Poiraudeau
S, Briot
K, Roux
C. Barriers to effective postmenopausal osteoporosis treatment: a qualitative study of patients’ and practitioners’ views. PLOS ONE
2016;11:e0158365.
[
PMC free article: PMC4927112] [
PubMed: 27355576]
- 71.
Guzman-Clark
JRS, Fang
MA, Sehl
ME, Traylor
L, Hahn
TJ. Barriers in the management of glucocorticoid-induced osteoporosis. Arthritis Care Res
2007;57:140–6. [
PubMed: 17266078]
- 72.
Lau
E, Papaioannou
A, Dolovich
L, Adachi
J, Sawka
AM, Burns
S, et al. Patients’ adherence to osteoporosis therapy: exploring the perceptions of postmenopausal women. Can Fam Physician
2008;54:394–402.
[
PMC free article: PMC2278357] [
PubMed: 18337534]
- 73.
Salter
C, McDaid
L, Bhattacharya
D, Holland
R, Marshall
T, Howe
A. Abandoned acid? Understanding adherence to bisphosphonate medications for the prevention of osteoporosis among older women: a qualitative longitudinal study. PLOS ONE
2014;9:e83552. 10.1371/journal.pone.0083552
[
PMC free article: PMC3879247] [
PubMed: 24392086] [
CrossRef]
- 74.
Iversen
MD, Vora
RR, Servi
A, Solomon
DH. Factors affecting adherence to osteoporosis medications: a focus group approach examining viewpoints of patients and providers. J Geriatr Phys Ther
2011;34:72–81.
[
PMC free article: PMC3181084] [
PubMed: 21937896]
- 75.
Mazor
KM, Velten
S, Andrade
SE, Yood
RA. Older women’s views about prescription osteoporosis medication: a cross-sectional, qualitative study. Drugs Aging
2010;27:999–1008.
[
PubMed: 21087069]
- 76.
Wozniak
LA, Johnson
JA, McAlister
FA, Beaupre
LA, Bellerose
D, Rowe
BH, Majumdar
SR. Understanding fragility fracture patients’ decision-making process regarding bisphosphonate treatment. Osteoporos Int
2017;28:219–29.
[
PMC free article: PMC5206259] [
PubMed: 27423660]
- 77.
Swart
KMA, Van Vilsteren
M, Van Hout
W, Draak
E, van der Zwaard
BC, van der Horst
HE, et al. Factors related to intentional non-initiation of bisphosphonate treatment in patients with a high fracture risk in primary care: a qualitative study. BMC Fam Pract
2018;19:141–9.
[
PMC free article: PMC6108118] [
PubMed: 30139341]
- 78.
- 79.
Sale
JEM, Gignac
MA, Hawker
G, Frankel
L, Beaton
D, Bogoch
E, Elliot-Gibson
V. Decision to take osteoporosis medication in patients who have had a fracture and are ‘high’ risk for future fracture: a qualitative study. BMC Musculoskelet Disord
2011;12:92. 10.1186/1471-2474-12-92
[
PMC free article: PMC3103493] [
PubMed: 21554729] [
CrossRef]
- 80.
Sturrock
A, Preshaw
P, Hayes
C, Wilkes
S. Attitudes and perceptions of GPs and community pharmacists towards their role in the prevention of bisphosphonate-related osteonecrosis of the jaw: a qualitative study in the North East of England. BMJ Open
2017;7:e016047. [
PMC free article: PMC5640123] [
PubMed: 28965092]
- 81.
Sturrock
A, Preshaw
PM, Hayes
C, Wilkes
S. Perceptions and attitudes of patients towards medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in England. BMJ Open
2019;9:e024376. [
PMC free article: PMC6443056] [
PubMed: 30833319]
- 82.
Nunes
V, Neilson
J, O’flynn
N. Medicines Adherence: Involving Patients in Decisions about Prescribed Medicines and Supporting Adherence (CG76). NICE Guidance; 2009. URL:
http://nice.org.uk/guidance/cg76 (accessed 25 May 2023).
- 83.
Horne
R, Cooper
V, Wileman
V, Parham
R, Freemantle
N, Forbes
A, Cooper
V. Supporting adherence to medicines for long-term conditions. Eur Psychol
2019;24:82–96. 10.1027/1016-9040/a000353 [
CrossRef]
- 84.
Driesenaar
JA, De Smet
PA, van Hulten
R, Horne
R, Zwikker
H, van den Bemt
B, van Dulmen
S. Beliefs about inhaled corticosteroids: comparison of community pharmacists, pharmacy technicians and patients with asthma. J Asthma
2016;53:1051–8.
[
PubMed: 27187172]
- 85.
Checkland
K, Harrison
S, Marshall
M. Is the metaphor of ‘barriers to change’ useful in understanding implementation? Evidence from general medical practice. J Heal Serv Res Policy
2007;12:95–00. [
PubMed: 17407659]
- 86.
- 87.
Sekhon
M, Cartwright
M, Francis
JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res
2017;17:1–13.
[
PMC free article: PMC5267473] [
PubMed: 28126032]
- 88.
Roh
YH, Noh
JH, Gong
HS, Baek
GH. Comparative adherence to weekly oral and quarterly intravenous bisphosphonates among patients with limited heath literacy who sustained distal radius fractures. J Bone Miner Metab
2018;36:589–95.
[
PubMed: 28983705]
- 89.
- 90.
Kendler
DL, Bessette
L, Hill
CD, Gold
DT, Horne
R, Varon
SF, et al. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos Int
2010;21:837–46.
[
PubMed: 19657689]
- 91.
Payer
J, Cierny
D, Killinger
Z, Sulková
I, Behuliak
M, Celec
P. Preferences of patients with post-menopausal osteoporosis treated with bisphosphonates – the VIVA II study. J Int Med Res
2009;37:1225–9.
[
PubMed: 19761708]
- 92.
Fjose
M, Eilertsen
G, Kirkevold
M, Grov
EK. ‘Non-palliative care’ – a qualitative study of older cancer patients’ and their family members’ experiences with the health care system. BMC Health Serv Res
2018;18:745.
[
PMC free article: PMC6162914] [
PubMed: 30268149]
- 93.
Selman
LE, Bristowe
K, Higginson
IJ, Murtagh
FEM. The views and experiences of older people with conservatively managed renal failure: a qualitative study of communication, information and decision-making. BMC Nephrol
2019;20:1–12.
[
PMC free article: PMC6360769] [
PubMed: 30717686]
- 94.
- 95.
Fallowfield
L, Stebbing
J, Braybrooke
J, Langridge
C, Jenkins
V. The preferences and experiences of different bisphosphonate treatments in women with breast cancer. Psycho-Oncology
2011;20:755–61.
[
PubMed: 20878871]
- 96.
Horne
R, Chapman
SCE, Parham
R, Freemantle
N, Forbes
A, Cooper
V. Understanding patients’ adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLOS ONE
2013;8:e80633.
[
PMC free article: PMC3846635] [
PubMed: 24312488]
- 97.
Qaseem
A, Forciea
MA, McLean
RM, Denberg
TD, Barry
MJ, Cooke
M, et al.; Clinical Guidelines Committee of the American College of Physicians. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med
2017;166:818–39.
[
PubMed: 28492856]
- 98.
- 99.
Koller
G, Goetz
V, Vandermeer
B, Homik
J, McAlister
FA, KendlerYe
DC. Persistence and adherence to parenteral osteoporosis therapies: a systematic review. Osteoporos Int
2020;31:2093–102.
[
PubMed: 32613409]
- 100.
Vrijens
B, De Geest
S, Hughes
DA, Przemyslaw
K, Demonceau
J, Ruppar
T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol
2012;73:691–705.
[
PMC free article: PMC3403197] [
PubMed: 22486599]
- 101.
De Geest
S, Zullig
LL, Dunbar-Jacob
J, Helmy
R, Hughes
DA, Wilson
IB, Vrijens
B. ESPACOMP medication adherence reporting guideline (EMERGE). Ann Intern Med
2018;169:30–5.
[
PMC free article: PMC7643841] [
PubMed: 29946690]
- 102.
Hiligsmann
M, Cornelissen
D, Vrijens
B, Abrahamsen
B, Al- Daghri
N, Biver
E, et al. Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). Osteoporos Int
2019;30:2155–65.
[
PMC free article: PMC6811382] [
PubMed: 31388696]
- 103.
Chaimani
A, Caldwell
DM, Li
T, Higgins
JPT, Salanti
G, Higgins
JP, et al. Cochrane Handbook for Systematic Reviews of Interventions. Hoboken: John Wiley & Sons; 2019.
- 104.
McGuinness
LA, Higgins
JP. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods
2021;12:55–61.
[
PubMed: 32336025]
- 105.
White
IR. Network meta-analysis. Stata J
2015;15:951–85.
- 106.
Hutton
B, Salanti
G, Caldwell
DM, Chaimani
A, Schmid
CH, Cameron
C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med
2015;162:777–84.
[
PubMed: 26030634]
- 107.
Higgins
JT, Altman
D, Group CSM, Group CBM. Chapter 8: Assessing risk of bias in included studies. In Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: The Cochrane Collaboration and John Wiley & Sons Ltd; 2011.
- 108.
Sterne
JA, Hernán
MA, Reeves
BC, Savović
J, Berkman
ND, Viswanathan
M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ
2016;355:23–9. [
PMC free article: PMC5062054] [
PubMed: 27733354]
- 109.
Dias
S, Welton
NJ, Sutton
AJ, Ades
AE. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. (Technical Support Document in Evidence Synthesis; No. TSD2). London: National Institute for Health and Clinical Excellence; 2012. [
PubMed: 27466657]
- 110.
Dias
S, Sutton
AJ, Welton
NJ, Ades
AE. Evidence synthesis for decision making 3: heterogeneity – subgroups, meta-regression, bias, and bias-adjustment. Med Decis Making
2013;33:618–40.
[
PMC free article: PMC3704206] [
PubMed: 23804507]
- 111.
Salanti
G, Ades
AE, Ioannidis
JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol
2011;64:163–71.
[
PubMed: 20688472]
- 112.
Dias
S, Ades
AE, Welton
NJ, Jansen
JP, Sutton
AJ. Chapter 4. Generalised Linear Models. Network Meta-Analysis for Decision-Making. Oxford, UK: John Wiley & Sons Ltd.; 2018.
- 113.
Dakin
HA, Welton
NJ, Ades
AE, Collins
S, Orme
M, Kelly
S. Mixed treatment comparison of repeated measurements of a continuous endpoint: an example using topical treatments for primary open-angle glaucoma and ocular hypertension. Stat Med
2011;30:2511–35.
[
PubMed: 21728183]
- 114.
Dias
S, Ades
AE, Welton
NJ, Jansen
JP, Sutton
AJ. Chapter 8. Meta-Regression for Relative Treatment Effects. Network Meta-Analysis for Decision-Making. Oxford, UK: John Wiley & Sons Ltd.; 2018.
- 115.
McKenzie
JE, Brennan
SE. Chapter 12: Synthesizing and presenting findings using other methods. In Higgins
JP, Thomas
J, Chandler
J, Cumpston
M, Li
T, Page
MJ, Welch
VA, editors. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons; 2019. URL:
https://training.cochrane.org/handbook/current (accessed 1 August 2020).
- 116.
- 117.
Dias
S, Welton
NJ, Caldwell
DM, Ades
AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med
2010;29:932–44.
[
PubMed: 20213715]
- 118.
Dias
S, Ades
AE, Welton
NJ, Jansen
JP, Sutton
AJ. Chapter 7. Checking for Inconsistency. Network Meta-Analysis for Decision-Making. Oxford, UK: John Wiley & Sons Ltd.; 2018.
- 119.
van Valkenhoef
G, Dias
S, Ades
AE, Welton
NJ. Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. Res Synth Methods
2016;7:80–93.
[
PMC free article: PMC5057346] [
PubMed: 26461181]
- 120.
Nikolakopoulou
A, Higgins
JP, Papakonstantinou
T, Chaimani
A, Del Giovane
C, Egger
M, Salanti
G. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLOS Med
2020;17:e1003082.
[
PMC free article: PMC7122720] [
PubMed: 32243458]
- 121.
Papakonstantinou
T, Nikolakopoulou
A, Higgins
JP, Egger
M, Salanti
G. CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis. Campbell System Rev
2020;16:e1080.
[
PMC free article: PMC8356302] [
PubMed: 37131978]
- 122.
Tan
W, Sun
J, Zhou
L, Li
Y, Wu
X. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with postmenopausal osteoporosis. J Clin Pharm Ther
2016;41:519–23.
[
PubMed: 27440710]
- 123.
Hu
W, Wang
H, Shi
X, Song
Y, Zhang
G, Xing
S, et al. Effect of preoperative zoledronic acid administration on pain intensity after percutaneous vertebroplasty for osteoporotic vertebral compression fractures. Pain Res Manag
2020;2020:1–8. [
PMC free article: PMC7421713] [
PubMed: 32831984]
- 124.
Li
H, Li
C, Yi
X, Liu
H, Wang
Y. Effects of sodium alendronate on osteoporosis and apoptosisrelated factors Cyt C, Apaf-1 and caspase-9. Biomed Res
2018;29:121–9.
- 125.
Li
Y, Zhao
WB, Wang
DL, He
Q, Li
Q, Pei
FX, Liu
L. Treatment of osteoporotic intertrochanteric fractures by zoledronic acid injection combined with proximal femoral nail antirotation. Chin J Traumatol
2016;19:259–63.
[
PMC free article: PMC5068210] [
PubMed: 27780504]
- 126.
Liang
BC, Shi
ZY, Wang
B, Wu
P, Kong
LC, Yao
JL, et al. Intravenous zoledronic acid 5 mg on bone turnover markers and bone mineral density in East China subjects with newly diagnosed osteoporosis: a 24-month Clinical Study. Orthop Surg
2017;9:103–9.
[
PMC free article: PMC6584087] [
PubMed: 28276638]
- 127.
Liu
Z, Li
CW, Mao
YF, Liu
K, Liang
BC, Wu
LG, Shi
XL. Study on zoledronic acid reducing acute bone loss and fracture rates in elderly postoperative patients with intertrochanteric fractures. Orthop Surg
2019;11:380–5.
[
PMC free article: PMC6595103] [
PubMed: 31058448]
- 128.
Shi
ZY, Zhang
XG, Li
CW, Liu
K, Liang
BC, Shi
XL. Effect of traditional Chinese medicine product, QiangGuYin, on bone mineral density and bone turnover in Chinese postmenopausal osteoporosis. Evid Based Complementary Altern Med
2017;2017:1–8. [
PMC free article: PMC5415859] [
PubMed: 28512501]
- 129.
Zhang
J, Zhang
T, Xu
X, Cai
Q, Zhao
D. Zoledronic acid combined with percutaneous kyphoplasty in the treatment of osteoporotic compression fracture in a single T12 or L1 vertebral body in postmenopausal women. Osteoporos Int
2019;30:1475–80.
[
PubMed: 30976888]
- 130.
Zhang
ZL, Liao
EY, Xia
WB, Lin
H, Cheng
Q, Wang
L, et al. Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension. Osteoporos Int
2015;26:2719–20.
[
PMC free article: PMC4713924] [
PubMed: 26377424]
- 131.
Zhou
J, Liu
B, Qin
MZ, Liu
JP. Fall prevention and anti-osteoporosis in osteopenia patients of 80 years of age and older: a randomized controlled study. Orthop Surg
2020;12:890–9.
[
PMC free article: PMC7307256] [
PubMed: 32495521]
- 132.
Paggiosi
MA, Peel
N, McCloskey
E, Walsh
JS, Eastell
R. Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study. Osteoporos Int
2014;25:2729–41.
[
PubMed: 25074351]
- 133.
Eastell
R, Nagase
S, Ohyama
M, Small
M, Sawyer
J, Boonen
S, et al. Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study. J Bone Miner Res
2011;26:1303–12.
[
PubMed: 21312264]
- 134.
Cesareo
R, Di Stasio
E, Vescini
F, Campagna
G, Cianni
R, Pasqualini
V, et al. Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism. Osteoporos Int
2015;26:1295–302.
[
PubMed: 25524023]
- 135.
Livi
L, Scotti
V, Desideri
I, Saieva
C, Cecchini
S, Francolini
G, et al. Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial. Eur J Cancer
2019;108:100–10.
[
PubMed: 30648627]
- 136.
Popp
AW, Buffat
H, Cavelti
A, Windolf
M, Perrelet
R, Senn
C, Lippuner
K. Cortical bone loss at the tibia in postmenopausal women with osteoporosis is associated with incident non-vertebral fractures: results of a randomized controlled ancillary study of HORIZON. Maturitas
2014;77:287–93.
[
PubMed: 24485216]
- 137.
Cosman
F, Gilchrist
N, McClung
M, Foldes
J, de Villiers
T, Santora
A, et al. A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates. Osteoporos Int
2016;27:377–86.
[
PubMed: 26556736]
- 138.
Greenspan
SL, Perera
S, Ferchak
MA, Nace
DA, Resnick
NM. Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial. JAMA Intern Med
2015;175:913–21.
[
PMC free article: PMC4843134] [
PubMed: 25867538]
- 139.
Greenspan
SL, Vujevich
KT, Brufsky
A, Lembersky
BC, van Londen
GJ, Jankowitz
RC, et al. Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial. Osteoporos Int
2015;26:1857–64.
[
PMC free article: PMC4766869] [
PubMed: 25792492]
- 140.
Grey
A, Bolland
M, Wong
S, Horne
A, Gamble
G, Reid
IR. Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab
2012;97:286–92.
[
PubMed: 22072741]
- 141.
Cheung
AS, Hoermann
R, Ghasem-Zadeh
A, Tinson
AJ, Ly
V, Milevski
SV, et al. Differing effects of zoledronic acid on bone microarchitecture and bone mineral density in men receiving androgen deprivation therapy: a randomized controlled trial. J Bone Miner Res
2020;35:1871–80.
[
PubMed: 32542695]
- 142.
Reid
IR, Horne
AM, Mihov
B, Stewart
A, Garratt
E, Wong
S, et al. Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med
2018;379:2407–16.
[
PubMed: 30575489]
- 143.
Nakamura
T, Fukunaga
M, Nakano
T, Kishimoto
H, Ito
M, Hagino
H, et al. Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study). Osteoporos Int
2017;28:389–98.
[
PMC free article: PMC5206287] [
PubMed: 27631091]
- 144.
Shin
K, Park
SH, Park
W, Baek
HJ, Lee
YJ, Kang
SW, et al. Monthly oral ibandronate reduces bone loss in Korean women with rheumatoid arthritis and osteopenia receiving long-term glucocorticoids: a 48-week double-blinded randomized placebo-controlled investigator-initiated trial. Clin Ther
2017;39:268–78.
[
PubMed: 28161119]
- 145.
McClung
MR, Grauer
A, Boonen
S, Bolognese
MA, Brown
JP, Diez-Perez
A, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med
2014;370:412–20.
[
PubMed: 24382002]
- 146.
Sestak
I, Singh
S, Cuzick
J, Blake
GM, Patel
R, Gossiel
F, et al. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. Lancet Oncol
2014;15:1460–8.
[
PubMed: 25456365]
- 147.
Black
DM, Reid
IR, Cauley
JA, Cosman
F, Leung
PC, Lakatos
P, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res
2015;30:934–44.
[
PubMed: 25545380]
- 148.
Grey
A, Bolland
M, Mihov
B, Wong
S, Horne
A, Gamble
G, Reid
IR. Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial. J Bone Miner Res
2014;29:166–72.
[
PubMed: 23761303]
- 149.
Grey
A, Bolland
MJ, Horne
A, Mihov
B, Gamble
G, Reid
IR. Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial. CMAJ
2017;189:E1130–6.
[
PMC free article: PMC5595552] [
PubMed: 28893875]
- 150.
Eastell
R, Nagase
S, Small
M, Boonen
S, Spector
T, Ohyama
M, et al. Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study. J Bone Miner Res
2014;29:458–66.
[
PubMed: 23873670]
- 151.
Kanis
JA, Harvey
NC, McCloskey
E, Bruyère
O, Veronese
N, Lorentzon
M, et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int
2020;31:1–2. [
PMC free article: PMC7018677] [
PubMed: 31720707]
- 152.
Kendler
DL, Marin
F, Zerbini
CA, Russo
LA, Greenspan
SL, Zikan
V, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet
2018;391:230–40.
[
PubMed: 29129436]
- 153.
Saag
KG, Petersen
J, Brandi
ML, Karaplis
AC, Lorentzon
M, Thomas
T, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med
2017;377:1417–27.
[
PubMed: 28892457]
- 154.
Banefelt
J, Åkesson
KE, Spångeus
A, Ljunggren
O, Karlsson
L, Ström
O, et al. Risk of imminent fracture following a previous fracture in a Swedish database study. Osteoporos Int
2019;30:601–9.
[
PMC free article: PMC6422949] [
PubMed: 30680431]
- 155.
Balasubramanian
A, Zhang
J, Chen
L, Wenkert
D, Daigle
SG, Grauer
A, Curtis
JR. Risk of subsequent fracture after prior fracture among older women. Osteoporos Int
2019;30:79–92.
[
PMC free article: PMC6332293] [
PubMed: 30456571]
- 156.
Noirmain
C, Gil-Wey
B, Pichon
I, Brindel
P, Haller
G. Factors associated with patient willingness to participate in anaesthesia clinical trials: a vignette-based cross-sectional study. BMC Med Res Methodol
2020;20:1–0. [
PMC free article: PMC7082904] [
PubMed: 32192447]
- 157.
Avis
NE, Smith
KW, Link
CL, Hortobagyi
GN, Rivera
E. Factors associated with participation in breast cancer treatment clinical trials. J Clin Oncol
2006;24:1860–7.
[
PubMed: 16622260]
- 158.
Curtis
JR, Yun
H, Matthews
R, Saag
KG, Delzell
E. Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population. Arthritis Care Res
2012;64:1054–60. [
PMC free article: PMC3355221] [
PubMed: 22328117]
- 159.
Selak
V, Elley
CR, Bullen
C, Crengle
S, Wadham
A, Rafter
N, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ
2014;348:g3318–g3318.
[
PubMed: 24868083]
- 160.
Watts
NB, Chines
A, Olszynski
WP, McKeever
CD, McClung
MR, Zhou
X, Grauer
A. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int
2008;19:365–72.
[
PubMed: 17938986]
- 161.
- 162.
Morley
J, Moayyeri
A, Ali
L, Taylor
A, Feudjo-Tepie
M, Hamilton
L, Bayly
J. Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK Clinical Practice Research Datalink. Osteoporos Int
2020;31:533–45. 10.1007/s00198-019-05228-8
[
PMC free article: PMC7076063] [
PubMed: 31758206] [
CrossRef]
- 163.
Guyot
P, Ades
AE, Ouwens
MJNM, Welton
NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol
2012;12:9. 10.1186/1471-2288-12-9
[
PMC free article: PMC3313891] [
PubMed: 22297116] [
CrossRef]
- 164.
Spångeus
A, Johansson
S, Woisetschläger
M. Adherence to and persistence with zoledronic acid treatment for osteoporosis – reasons for early discontinuation. Arch Osteoporos
2020;15:58. 10.1007/s11657-020-00733-4
[
PMC free article: PMC7165128] [
PubMed: 32303862] [
CrossRef]
- 165.
- 166.
Schwartz
AV, Bauer
DC, Cummings
SR, Cauley
JA, Ensrud
KE, Palermo
L, et al.; FLEX Research Group. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res
2010;25:976–82.
[
PubMed: 20200926]
- 167.
Black
DM, Reid
IR, Boonen
S, Bucci-Rechtweg
C, Cauley
JA, Cosman
F, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res
2012;27:243–54.
[
PMC free article: PMC3427916] [
PubMed: 22161728]
- 168.
Eastell
R, Hannon
RA, Wenderoth
D, Rodriguez-Moreno
J, Sawicki
A. Effect of stopping risedronate after long-term treatment on bone turnover. J Clin Endocrinol Metab
2011;96:3367–73.
[
PMC free article: PMC3205892] [
PubMed: 21865359]
- 169.
Ravn
P, Christensen
JO, Baumann
M, Clemmesen
B. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment. Bone
1998;22:559–64.
[
PubMed: 9600792]
- 170.
Davis
S, Simpson
E, Hamilton
J, Martyn-St James
M, Rawdin
A, Wong
R, et al. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation. Health Technol
2020;24:1–314. [
PMC free article: PMC7357239] [
PubMed: 32588816]
- 171.
Reginster
JY, Adami
S, Lakatos
P, Greenwald
M, Stepan
JJ, Silverman
SL, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis
2006;65:654–61. 10.1136/ard.2005.044958
[
PMC free article: PMC1798147] [
PubMed: 16339289] [
CrossRef]
- 172.
Delmas
PD, Adami
S, Strugala
C, Stakkestad
JA, Reginster
JY, Felsenberg
D, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum
2006;54:1838–46.
[
PubMed: 16729277]
- 173.
Eisman
JA, Civitelli
R, Adami
S, Czerwinski
E, Recknor
C, Prince
R, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol
2008;35:488–97.
[
PubMed: 18260172]
- 174.
Reid
IR, Gamble
GD, Mesenbrink
P, Lakatos
P, Black
DM. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab
2010;95:4380–7.
[
PubMed: 20554708]
- 175.
van Hoek
AJ, Underwood
A, Jit
M, Miller
E, Edmunds
WJ. The impact of pandemic influenza H1N1 on health-related quality of life: a prospective population-based study. PLOS ONE
2011;6:e17030. 10.1371/journal.pone.0017030
[
PMC free article: PMC3047534] [
PubMed: 21399678] [
CrossRef]
- 176.
- 177.
Gutiérrez
L, Roskell
N, Castellsague
J, Beard
S, Rycroft
C, Abeysinghe
S, et al. Study of the incremental cost and clinical burden of hip fractures in postmenopausal women in the United Kingdom. J Med Econ
2011;14:99–107.
[
PubMed: 21222505]
- 178.
Gutiérrez
L, Roskell
N, Castellsague
J, Beard
S, Rycroft
C, Abeysinghe
S, et al. Clinical burden and incremental cost of fractures in postmenopausal women in the United Kingdom. Bone
2012;51:324–31.
[
PubMed: 22684000]
- 179.
Ström
O, Borgström
F, Zethraeus
N, Johnell
O, Lidgren
L, Ponzer
S, et al. Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop
2008;79:269–80.
[
PubMed: 18484255]
- 180.
Svedbom
A, Borgstöm
F, Hernlund
E, Ström
O, Alekna
V, Bianchi
ML, et al. Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures-results from the ICUROS. Osteoporos Int
2018;29:557–66.
[
PubMed: 29230511]
- 181.
Abimanyi-Ochom
J, Watts
JJ, Borgström
F, Nicholson
GC, Shore-Lorenti
C, Stuart
AL, et al. Changes in quality of life associated with fragility fractures: Australian arm of the International Cost and Utility Related to Osteoporotic Fractures Study (AusICUROS). Osteoporos Int
2015;26:1781–90.
[
PMC free article: PMC4468793] [
PubMed: 25792491]
- 182.
National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal 2013. London: NICE; 2013. [
PubMed: 27905712]
- 183.
Strong
M, Oakley
JE, Brennan
A. Estimating multiparameter partial expected value of perfect information from a probabilistic sensitivity analysis sample: a nonparametric regression approach. Med Decis Making
2014;34:311–26.
[
PMC free article: PMC4819801] [
PubMed: 24246566]
- 184.
Doble
B, Payne
R, Harshfield
A, Wilson
ECF. Retrospective, multicohort analysis of the Clinical Practice Research Datalink (CPRD) to determine differences in the cost of medication wastage, dispensing fees and prescriber time of issuing either short (< 60 days) or long (≥ 60 days) prescription lengths in primary care for common, chronic conditions in the UK. BMJ Open
2017;7:e019382. [
PMC free article: PMC5719293] [
PubMed: 29208621]
- 185.
de Wit
MP, Berlo
SE, Aanerud
GJ, Aletaha
D, Bijlsma
JW, Croucher
L, et al. European league against rheumatism recommendations for the inclusion of patient representatives in scientific projects. Ann Rheum Dis
2011;70:722–6.
[
PubMed: 21257615]
- 186.
Crowe
S, Fenton
M, Hall
M, Cowan
K, Chalmers
I. Patients’, clinicians’ and the research communities’ priorities for treatment research: there is an important mismatch. Res Involv Engagem
2015;1:14.
[
PMC free article: PMC5611591] [
PubMed: 29082930]
- 187.
Hernlund
E, Svedbom
A, Ivergård
M, Compston
J, Cooper
C, Stenmark
J, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. Arch Osteoporos
2017;8:136–45. [
PMC free article: PMC3880487] [
PubMed: 24113837]
- 188.
Cooper
C. The crippling consequences of fractures and their impact on quality of life. Am J Med
1997;103:S12–9. [
PubMed: 9302893]
- 189.
- 190.
Mahmood
W, Jinks
C, Jayakumar
P, Gwilym
S, Paskins
Z. 115 public priority setting for research in osteoporosis. Rheumatology
2016;55:109–i110.
- 191.
Jinks
C, Carter
P, Rhodes
C, Taylor
R, Beech
R, Dziedzic
K, et al. Patient and public involvement in primary care research-an example of ensuring its sustainability. Res Involv Engagem
2016;2:1.
[
PMC free article: PMC5611572] [
PubMed: 29062502]
- 192.
Chalmers
I, Bracken
MB, Djulbegovic
B, Garattini
S, Grant
J, Gülmezoglu
AM, et al. How to increase value and reduce waste when research priorities are set. Lancet
2014;383:156–65.
[
PubMed: 24411644]
- 193.
Partridge
N, Scadding
J. The James Lind Alliance: patients and clinicians should jointly identify their priorities for clinical trials. Lancet
2014;364:1923–4. [
PubMed: 15566996]
- 194.
Staley
K, Hanley
B. Scoping Research Priority Setting (and the Presence of PPI in Priority Setting) with UK Clinical Research Organisations and Funders; 2018. James Lind Alliance Oxford.
- 195.
Paskins
Z, Jinks
C, Mahmood
W, Jayakumar
P, Sangan
CB, Belcher
J, Gwilym
S. Public priorities for osteoporosis and fracture research: results from a general population survey. Arch Osteoporos
2017;12:1–8.
[
PMC free article: PMC5409917] [
PubMed: 28455735]
- 196.
Katherine Cowan, Senior Advisor to JLA, Sandy Oliver, Professor of Public Policy at Social Science Research Unit and EPPI-Centre, Institute of Education, University of London; James Lind Alliance (JLA) Guidebook, Chapter 1. Katherine oversaw versions 1 – 5. The JLA team at the School of Healthcare Enterprise and Innovation, University of Southampton, and Katherine Cowan, with input from the JLA Advisers, have updated versions 6 onwards. URL:
http://jla.nihr.ac.uk/jla-guidebook/downloads/JLA-Guidebook-Version-10-March-2021.pdf (accessed 25 May 2023).
- 197.
Richardson
WS, Wilson
MC, Nishikawa
J, Hayward
RS. The well-built clinical question: a key to evidence-based decisions. ACP J Club
1995;123:A12–3. [
PubMed: 7582737]
- 198.
Katherine Cowan, Senior Advisor to JLA, Sandy Oliver, Professor of Public Policy at Social Science Research Unit and EPPI-Centre, Institute of Education, University of London; James Lind Alliance (JLA) Guidebook, Chapter 7 Report on JLA PSP online priority setting workshop – Caroline Whiting, School of Healthcare Enterprise and Innovation, University of Southampton. URL:
www.jla.nihr.ac.uk/jla-guidebook/downloads/JLS-Guidebook-Version-10-2021.pdf (accessed 25 May 2023).
- 199.
- 200.
National Institute for Health and Care Excellence (NICE). Alendronate, Etidronate, Risedronate, Raloxifene, Strontium Ranelate and Teriparatide for the Secondary Prevention of Osteoporotic Fragility Fractures in Postmenopausal Women. 2008. TAG 161. URL:
www.nice.org.uk/guidance/ta464 (accessed 1 August 2022).
- 201.
Grossman
JM, Gordon
R, Ranganath
VK, Deal
C, Caplan
L, Chen
W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res
2010;62:1515–26. [
PubMed: 20662044]
- 202.
Paskins
Z, Babatunde
O, Sturrock
A, Toh
LS, Horne
R, Maidment
I, et al., On behalf of the Effectiveness Working Group of the Royal Osteoporosis Society Osteoporosis and Bone Research Academy. Supporting patients to get the best from their osteoporosis treatment: a rapid realist review. Osteoporos Int
2022;33:2245–57.
[
PMC free article: PMC9568441] [
PubMed: 35688897]
- 203.
Paskins
Z, Bullock
L, Crawford-Manning
F, Cottrell
E, Fleming
J, Leyland
S, et al. Improving uptake of fracture prevention drug treatments: a protocol for development of a consultation intervention (iFraP-D). BMJ Open
2021;11:e048811. 10.1136/bmjopen-2021-048811 [
PMC free article: PMC8375717] [
PubMed: 34408051] [
CrossRef]
- 204.
Cornelissen
D, Boonen
A, Evers
S, van den Bergh
JP, Bours
S, Wyers
CE, et al. Improvement of osteoporosis Care Organized by Nurses: ICON study – protocol of a quasi-experimental study to assess the (cost)-effectiveness of combining a decision aid with motivational interviewing for improving medication persistence in patients with a recent fracture being treated at the fracture liaison service. BMC Musculoskelet Disord
2021;22:913. 10.1186/s12891-021-04743-2
[
PMC free article: PMC8555732] [
PubMed: 34715838] [
CrossRef]
- 205.
Sale
J, Marwah
A, Naeem
F, Yu
W, Meadows
L. Evidence of patient beliefs, values, and preferences is not provided in osteoporosis clinical practice guidelines. Osteoporos Int
2019;30:1325–37. 10.1007/s00198-019-04913-y
[
PubMed: 30859238] [
CrossRef]
